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Abstract 
 
The skin is a squamous epithelium that is continuously renewed by a 
population of basal layer stem/progenitor cells and can heal wounds. Here we 
show that YAP and TAZ are nuclear localised in the basal layer of skin and 
are elevated upon wound healing. Skin-specific deletion of both YAP and TAZ 
in adult mice slows proliferation of basal layer cells, leads to hair loss and 
impairs regeneration after wounding. Contact with the basal extracellular 
matrix and consequent Integrin-Src signalling is a key determinant of 
YAP/TAZ nuclear localisation in basal layer cells and in skin tumours. Contact 
with the basement membrane is lost in differentiating daughter cells, where 
YAP and TAZ become mostly cytoplasmic. In other types of squamous 
epithelia and squamous cell carcinomas, a similar control mechanism is 
present. In contrast, columnar epithelia differentiate an apical domain that 
recruits CRB3, MERLIN, KIBRA and SAV to induce Hippo signalling and 
retain YAP/TAZ in the cytoplasm despite contact with the basal layer 
extracellular matrix. When columnar epithelial tumours lose their apical 
domain and become invasive, YAP/TAZ becomes nuclear and tumour growth 
becomes sensitive to the Src inhibitor Dasatinib.   
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Introduction 
 
The YAP family of transcriptional co-activators are emerging as potent 
oncoproteins that strongly drive cell proliferation in many types of 
stem/progenitor cells and cancers (Harvey et al., 2013; Irvine and Harvey, 
2015; Pan, 2010, 2015; Piccolo et al., 2013). The function of YAP family co-
activators was first discovered by Drosophila genetics, where the sole YAP 
homologue – Yorkie (Yki) – was found to be necessary and sufficient to 
promote cell proliferation and tissue overgrowth in epithelia (Huang et al., 
2005). Subsequent genetic experiments in mice showed that ectopic 
expression of YAP was sufficient to drive cell proliferation in liver, intestine, 
bronchus and skin (Cai et al., 2010; Camargo et al., 2007; Dong et al., 2007; 
Schlegelmilch et al., 2011; Zhang et al., 2011a; Zhao et al., 2014).  
Surprisingly, YAP knockout mice were shown to have mild phenotypes, 
although they were deficient in proliferative repair of the intestine and resistant 
to intestinal tumour formation (Azzolin et al., 2014; Cai et al., 2010) as well as 
showing reduced bronchial stem cells (Zhao et al., 2014) and kidney defects 
(Reginensi et al., 2015). An important and widespread physiological role for 
YAP in mice might be obscured by the possibility of redundancy between YAP 
and TAZ, a second mammalian family member that is highly similar in both 
sequence and function. 
 
At the molecular level, Yki and YAP were shown to function by associating 
with the DNA-binding transcription factor Scalloped (Sd; or TEAD in humans) 
to drive transcription of anti-apoptotic and pro-proliferative target genes 
(Koontz et al., 2013; Liu-Chittenden et al., 2012; Vassilev et al., 2001; Wu et 
al., 2008). Other co-factors of Yki/YAP that promote transcription include 
WBP2 (Zhang et al., 2011b), MASK1/2 (Sansores-Garcia et al., 2013; Sidor et 
al., 2013), and the SWI/SNF complex (Jin et al., 2013; Oh et al., 2013). The 
activity of Yki was found to be regulated by the Drosophila Hippo-Warts (Hpo-
Wts) kinase signalling pathway, in which Wts directly phosphorylates Yki to 
promote its relocalisation from the nucleus to the cytoplasm (Dong et al., 
2007; Huang et al., 2005; Oh and Irvine, 2008). In human cells in culture, YAP 
nuclear localisation is similarly inhibited upon LATS1/2 kinase phosphorylation, 
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because phosphorylated YAP is retained the cytoplasm by binding to 14-3-3 
family proteins (Dong et al., 2007; Zhao et al., 2007). This entire molecular 
system is now referred to as the Hippo signalling pathway. 
 
Much recent work has aimed to identify upstream regulators of Hippo 
signalling. A group of apically-localised proteins including Crumbs (Crb, 
CRB1/2/3 in humans), Merlin (Mer, NF2 in humans), Expanded (Ex, similar to 
Willin and AMOT in humans) and Kibra (Kib, KIBRA in humans) were found to 
activate Hippo signalling (repressing Yki activity) in Drosophila epithelia 
(Baumgartner et al., 2010; Chen et al., 2010; Genevet et al., 2010; 
Hamaratoglu et al., 2006; Ling et al., 2010; Varelas et al., 2010; Yu et al., 
2010) and in mice (Szymaniak et al., 2015). In addition, a group of adherens 
junction-localised proteins including Ajuba, Zyxin, Dachs, Mib and Riq, were 
shown to inhibit Hippo signalling (activating Yki) in Drosophila epithelia (Cho 
et al., 2006; Das Thakur et al., 2010; Degoutin et al., 2013; Gaspar et al., 
2015; Mao et al., 2006; Rauskolb et al., 2011). Finally, manipulation of the 
level of F-actin in Drosophila can also affect Hippo signalling, possibly via 
signalling through the Src kinase, which can promote Yki activation (Enomoto 
and Igaki, 2013; Fernandez et al., 2011; Fernandez et al., 2014; Sansores-
Garcia et al., 2011). Human YAP and TAZ were subsequently found to act as 
F-actin responsive mechanosensors in cell culture (Aragona et al., 2013; 
Benham-Pyle et al., 2015; Dupont et al., 2011; Zhao et al., 2007), but how 
their subcellular localisation is physiologically regulated in human epithelial 
tissues and cancers in vivo remains a fundamental unsolved problem. 
 
Here we examine the physiological function and regulation of YAP and TAZ in 
mammalian epithelial tissues. We focus on stratified squamous epithelia, 
particularly the skin, and compare our findings with columnar epithelia, such 
as the intestine and bronchus. We propose that YAP and TAZ act as sensors 
of both apical and basal signals in vivo, and that this regulatory logic explains 
why these proteins become nuclear localised in basal stem/progenitor cells to 
promote cell proliferation and tissue renewal. Elevation of YAP and TAZ can 
then drive increased cell proliferation during wound healing or tumour 
formation. 
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Results  
 
YAP and TAZ are expressed in both mouse and human skin, and 
regulate gene expression in basal layer stem/progenitor cells.  
We began by characterising the expression and subcellular localisation of 
YAP and TAZ in both mouse and human skin.  Both proteins were found to be 
expressed and nuclear localised in a subset of cells in the skin of the mouse 
embryo, neonate and adult. Nuclear localisation of YAP and TAZ was 
particularly prominent in basal layer cells of both interfollicular epidermis and 
the hair follicle (Fig 1A). Some nuclear localisation was also detected in the 
highly flattened squamous cells, consistent with results in cell culture where 
cell flattening induces nuclear accumulation of YAP and TAZ (Dupont et al., 
2011) (Fig 1A). Human YAP and TAZ show a similar pattern of subcellular 
localisation in sections of adult human skin (Fig 1B). Basal layer cells feature 
nuclear YAP and TAZ, while differentiating daughters feature cytoplasmic 
YAP and TAZ (Fig 1B). Again, some nuclear localisation is also detectable in 
highly flattened squamous cells that have terminally differentiated (Fig 1B). 
 
To confirm that YAP and TAZ are transcriptionally active in the skin, we 
sought to identify YAP-regulated genes by an RNA-sequencing (RNAseq) 
approach in human keratinocytes. mRNA was isolated from cells expressing 
activated YAP5SA or siRNAs against YAP and subjected to RNAseq and 
gene-set enrichment analysis (Fig 1C, S1). We find that the YAP-regulated 
gene sets included: the previously identified Hippo/YAP reactomes; cell cycle 
reactomes (such as E2F targets or CyclinE associated genes); cell growth 
reactomes (such as Myc, global translation regulators or regulation of 
ornithine decarboxylase); cancer signalling reactomes (such as EGFR-Ras 
signalling targets); and cancer microenvironment/metastasis reactomes 
(including regulators of cellular interactions with the extracellular matrix) (Fig 
S1). We therefore analysed the expression of the corresponding cell cycle 
(CycE1, PCNA, E2F1); cell growth (RPTOR, ODC1, ADC); EGFR and Integrin 
signalling (CYR61, CTGF, AREG, Integrins 3,6, 1, 2, 4) regulators (Fig 
1D).  We find a striking restriction of these YAP targets to the basal layer of 
D
ev
el
o
pm
en
t •
 A
dv
an
ce
 a
rt
ic
le
 
the skin, indicating that YAP/TAZ transcriptional regulation is active 
exclusively in the basal stem/progenitor cell population (Fig 1D). 
 
YAP and TAZ are required for skin homeostasis 
To examine the physiological role of YAP and TAZ, we generated double 
conditional knockout (dKO) mice with the skin-specific Keratin5-CreERT 
recombinase. Compared with control animals, the YAP/TAZ cKO mice 
showed a dramatic loss of hair in patches beginning 2 weeks after tamoxifen 
injection in adult mice, or causing complete blockade of hair growth in 
neonates treated with tamoxifen (Fig 2A,B). Histological sections of the skin 
revealed expression and nuclear localisation of YAP and TAZ in control skin 
which is lost in the dKO tissue. Proliferation of basal layer cells, as marked by 
Ki67 staining, was clearly reduced in YAP/TAZ cKO skin (Fig 2A,B), as was 
YAP target gene expression (Fig S2). These phenotypes are reminiscent of 
skin-specific conditional knockouts of Integrin1 (ITGB1) (Brakebusch et al., 
2000; Grose et al., 2002; Piwko-Czuchra et al., 2009; Raghavan et al., 2000; 
Singh et al., 2009). 
 
We next tested whether YAP and TAZ contribute to skin repair after wounding.  
We find that both YAP and TAZ levels become elevated after wounding, 
particularly in the basal cell layer of the epidermis where strong nuclear 
staining is visible (Fig 2C,D). We next recorded the time taken to repair small 
(4mm) wounds in the back skin of control versus YAP/TAZ dKO mice. We find 
that control wounds normally heal completely by 10 days, while dKO wounds 
fail to heal within 10 days and instead require an additional 2 days to heal (Fig 
2E,F). This delay in healing was not observed when YAP or TAZ were deleted 
individually. To investigate the cause of the delay in wound healing, we 
examined cell proliferation in control versus dKO wounds. We find that the 
number of Ki67-positive cells was reduced in dKO wounds versus controls 
(Fig 2G). These findings demonstrate a crucial, physiological requirement for 
YAP and TAZ in basal layer stem/progenitor cells to promote cell proliferation.   
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In the case of Integrin1 (ITGB1) conditional knockout skin, cells that escape 
Cre-mediated recombination are able to repopulate the mutant skin in a short 
timeframe (Piwko-Czuchra et al., 2009). We find that the same phenomenon 
occurs in YAP/TAZ dKO skin, where after Cre activation and YAP/TAZ 
deletion, either YAP or TAZ positive residual cells expand in territory, 
consistent with the notion that YAP and TAZ promote proliferation of basal 
layer cells (Fig S3). This phenomenon was also evident during wound healing, 
where YAP or TAZ positive cells were able to populate the wound and allow 
proliferation and healing in dKO animals (Fig S3). These findings underscore 
the importance of YAP and TAZ in epidermal progenitor cell proliferation and 
skin homeostasis and suggest a close relationship between Integrin signalling 
and YAP/TAZ function. 
 
Mechanisms controlling YAP nuclear localisation in basal layer cells 
We next sought to understand how YAP and TAZ become nuclear localised in 
basal layer cells. Since YAP and TAZ are similar proteins that localise 
identically in skin, we henceforth focus on regulation of YAP localisation.  
Recent work in cultured MCF10A breast cancer cells indicated a role for 
Integrin-Src signalling and EGFR-PI3K signalling in promoting YAP nuclear 
localisation (Fan et al., 2013; Kim and Gumbiner, 2015). To test whether 
these pathways are active in skin, we examined their expression and 
subcellular localisation.  Mining the Human Protein Atlas dataset, we find that 
ITGB1, SRC, EGFR and AKT2 (a marker of PI3K activation) are all expressed 
strongly in basal layer cells, with AKT2 recruited to the interface between 
basal layer epidermal cells and the underlying basement membrane 
extracellular matrix (Fig 3A-E). This pattern is also evident in other squamous 
epithelia such as cervix or oesophagus and is retained in squamous cell 
carcinomas (Fig 3A-E). These data suggest that nuclear YAP localisation may 
be stimulated by Integrin-Src and/or PI3K signalling in basal layer skin 
keratinocytes (Fig 3F).   
 
To confirm that Integrin-Src and PI3K signalling pathways are required for 
YAP nuclear localisation in keratinocytes, we systematically manipulated 
D
ev
el
o
pm
en
t •
 A
dv
an
ce
 a
rt
ic
le
 
these pathways with siRNA knockdown or treatment with specific inhibitor 
compounds in human keratinocytes in culture. We find that inhibition of 
Integrin1 (ITGB1) with blocking antibodies or siRNA, inhibition of the 
downstream effectors SRC or FAK, or inhibition of PI3K profoundly impairs 
YAP nuclear localisation (Fig 4A,B). Interestingly, inhibition of the PI3K 
effectors AKT and TORC1 had no effect on YAP localisation, while inhibition 
of PDK1 did partially impair YAP nuclear localisation (Fig 4C). Notably, drugs 
inhibiting F-actin, Myosin-II, or Rho-kinase had only a moderate effect on YAP 
localisation in keratinocytes (Fig 4D). Quantification of these phenotypes 
highlights the strong effect of Integrin-Src and PI3K inhibition (Fig 4E). Both 
Src inhibitors and PI3K inhibitors lead to a clear increase in phosphorylated 
YAP (p-YAP) indicating that Hippo signalling (MST-LATS signalling) is 
elevated by these treatments (Fig 4F). We confirmed these findings in a 
classic ‘scratch-wound’ assay, where Src inhibition completley reversed the 
nuclear localisation of YAP at the leading edge (Fig 4G). These findings 
indicate that Integrin-Src and EGFR-PI3K signalling are essential for YAP 
nuclear localisation in keratinocytes (Fig 4H). 
 
To extend these findings in vivo, we examined the role of Integrin-Src 
signalling in mouse skin. We compared YAP localisation in untreated and 
TPA-treated (inflamed) skin samples from control animals and knockouts for 
FAK or Src (Fig 5A-C). We find that loss of FAK or Src results in decreased 
YAP levels and nuclear localisation in both normal and inflamed skin (Fig 5A-
C). Some nuclear YAP remained in flattened cells (Fig 5A-C asterix). Similar 
results were obtained by treatment of mice with topical Src inhibitor 
(Dasatinib), which was able to drastically reduce YAP levels and nuclear 
localisation in untreated or TPA-treated skin, as well as in skin papillomas 
induced by a TPA+DMBA treatment regimen (Fig 5D-I). These findings show 
that Integrin-Src signalling is crucial to promote YAP stabilisation and nuclear 
localisation in basal layer stem/progenitor cells. Accordingly, recent work 
indicates that skin papillomas induced by DMBA+TPA in mice can be strongly 
reduced in size and frequency by homozygous deletion of YAP along with one 
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copy of TAZ, or by treatment with Dasatinib (Creedon and Brunton, 2012; 
Serrels et al., 2009; Zanconato et al., 2015). 
 
 
Mechanisms controlling YAP cytoplasmic localisation in differentiating 
daughter cells of squamous versus columnar epithelia 
The above analysis suggests that daughter cells differentiate in the skin 
simply by loss of contact with the basement membrane extracellular matrix 
and consequent loss of Integrin-Src signalling, EGFR-PI3K signalling and 
YAP nuclear localisation. This model is plausible in all stratified squamous 
epithelia, but cannot explain the self-renewal versus differentiation decision in 
columnar epithelia – because differentiated columnar epithelial cells retain 
contact with the basement membrane. Thus, columnar cells must employ an 
additional mechanism to promote YAP localisation to the cytoplasm. An 
obvious candidate is the expression of a differentiated apical plasma 
membrane domain in columnar epithelial cells, because apical proteins 
associated with Crumbs (CRB3) are well known to induce Hippo signalling 
(MST-LATS signalling) to drive YAP to the cytoplasm (Chen et al., 2010; 
Fletcher et al., 2015; Ling et al., 2010; Szymaniak et al., 2015; Varelas et al., 
2010).   
 
To test this notion in vivo, we compared the subcellular localisation of YAP 
with that of CRB3 in colunmar epithelia such as gallbladder, endometrium, 
lung bronchus, breast duct, urinary bladder, small intestine, colon and salivary 
gland. In all cases, apical localisation of CRB3 in differentiated daughter cells 
correlates with cytoplasmic localisation of YAP (Fig 6A-H). Accordingly, basal 
layer stem/progenitor cells of the lung, breast or intestine retain nuclear YAP 
but lack apical CRB3. Notably, CRB3 is not expressed in squamous epithelia 
so cannot mediate the regulation of YAP in these tissues (Fig 6I-L). The key 
Hippo pathway components MERLIN, SAV1 and KIBRA co-localise with 
CRB3 (Fig S4, S5) (Chen et al., 2010; Genevet et al., 2010; Hamaratoglu et 
al., 2006; Ling et al., 2010; Yin et al., 2013; Yu et al., 2010; Zhang et al., 
2010). These results indicate that a universal regulatory logic exists in which 
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YAP nuclear localisation requires contact with the basement membrane but is 
inhibited by expression of an apical domain (Fig 6M).   
 
We next sought to confirm that apical and basal signal act antagonistically in 
colunmar epithelial cells. We examined human intestinal epithelial cells in 
culture that are capable of forming 3D cysts or 2D monolayers in which YAP 
becomes cytoplasmic. We find that siRNA knockdown of the apical 
determinant Cdc42 or LATS1/2 have similar effects, driving YAP to the 
nucleus (Fig 7A,B). Strong YAP nuclear localisation can also be achieved 
simply by plating these cells at low density, so that they are unable to 
differentiate an apical domain and also retain a flat morphology with an 
extensive basal surface area (Fig 7C). This basal contact appears to invoke 
the same Integrin-Src signals identified in keratinocytes, because blocking of 
Integrins with low Ca2+, anti-ITGB1 antibodies, or ITGB1 siRNAs relocalises 
YAP to the cytoplasm (Fig 7C). Inhibition of Src, FAK, PI3K or PDK1 also 
impairs YAP nuclear localisation (Fig 7D,E). These effects are once again as 
strong as inhibition of F-actin, Myosin-II or Rho-kinase (Fig 7F,G). 
Examination of phospho-YAP levels indicates that Integrin-Src signalling acts 
via regulation of MST-LATS phosphorylation of YAP (Fig 7H). These results 
suggest that apical domain formation activates LATS kinases to retain YAP in 
the cytoplasm, while basal Integrin-Src and PI3K signalling inhibits LATS 
kinases to promote nuclear YAP localisation (Fig 7I).   
 
To further explore these findings in vivo, we examined how YAP behaves in 
columnar epithelial tumours that progress to invasive adenocarcinomas. We 
find that YAP remains cytoplasmic while tumours of the colon, stomach, lung, 
endometrium, urothelium or ovary retain their columnar epithelial form (Fig 
8A-F). In contrast, invasive adenocarcinomas of the same tissue origin all 
feature a loss of columnar form and a dramatic localisation of YAP to the 
nucleus (Fig 8A-F). These results suggest that loss of the apical domain 
during tumour progression allows YAP to become nuclear. We therefore 
tested whether nuclear YAP in invasive adenocarcinomas would be sensitive 
to inhibition of Integrin-Src signalling with Dasatinib. We examined Apc-/- P53-/-  
mutant intestinal organoids that have been implanted subcutaneously into 
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nude mice. On transplantation these organoids rapidly produce highly 
invasive adenocarcinomas, entering the surrounding stromal tissue. We find 
that YAP localisation becomes strongly nuclear specifically in the invasive 
tumour cells (Fig 8G). We next treated mice carrying such invasive tumours 
with the Src inhibitor Dasatinib, which strongly suppressed nuclear YAP 
localisation and reduced tumour growth and invasion (Fig 8H). These findings 
indicate that Src activity promotes YAP nuclear localisation in vivo and 
suggest a potential therapy for invasive adenocarcinomas and carcinomas. 
 
Discussion 
Our results identify a physiological role for YAP and TAZ in skin homeostasis, 
promoting cell proliferation in basal layer stem/progenitor cells (Figs 1&2). 
YAP and TAZ localise to the nucleus of basal layer cells to drive transcription 
of a set of genes associated with cell cycle progression, cell growth, EGFR 
signalling and cell-matrix adhesion via Integrins. In the absence of YAP and 
TAZ, proliferation is reduced and dramatic hair loss occurs, indicating that 
YAP and TAZ are crucial players in the stem/progenitor cell biology of the skin. 
Importantly, loss of either YAP or TAZ individually had no visible phenotype, 
confirming that the two proteins act in a redundant fashion in this tissue. 
 
Both YAP and TAZ localise to the nucleus in the basal layer cells of the skin, 
and we have focused on YAP to characterize the molecular mechanisms 
responsible for this nuclear localisation (Figs 3-5). We have examined the 
model that Integrin-Src and EGFR-PI3K signalling promotes YAP nuclear 
localisation – first proposed based on experiments in MCF10A breast cells in 
culture (Fan et al., 2013; Kim and Gumbiner, 2015) – and found that these 
signalling molecules are indeed strongly expressed in basal layer skin cells 
and are essential to promote YAP nuclear localisation in keratinocytes in 
culture and in mouse basal layer skin cells in vivo. Since YAP appears to 
induce expression of Integrins, Integrin ligands (CYR61, CTGF), and EGFR 
ligands (AREG), we propose that a positive feedback loop drives basal layer 
stem/progenitor cell identity, and that this loop is broken when daughter cells 
lose contact with the basement membrane and differentiate – forming a 
bistable system of cell fate determination. Our findings provide an explanation 
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for how these signalling pathways integrate to control skin stem/progenitor cell 
biology. 
 
The notion that nuclear localisation of YAP occurs upon contact with 
basement membrane extracellular matrix applies equally to other squamous 
epithelia. In contrast, columnar epithelia differentiate an apical domain that 
induces YAP relocalisation to the cytoplasm via apical CRB3-MER-KIBRA-
SAV signals, which are known to activate the MST and LATS kinases to 
promote YAP phosphorylation and cytoplasmic retention despite contact with 
the basement membrane (Fig 6&7, S4-S6) (Baumgartner et al., 2010; Chen et 
al., 2010; Fletcher et al., 2015; Genevet et al., 2010; Hamaratoglu et al., 2006; 
Ling et al., 2010; Sun et al., 2015; Szymaniak et al., 2015; Varelas et al., 
2010; Yin et al., 2013; Yu et al., 2010). The CRB3-MER-KIBRA-SAV complex 
appears to be absent in squamous epithelia, which never differentiate a true 
apical domain, leaving basement membrane contact as the sole regulatory 
mechanism (Fig 6). Thus, our results show that antagonistic apical and basal 
polarity signals serve as the primary control mechanism that determines YAP 
subcellular localisation in vivo. In a striking parallel, the same apical and basal 
polarity determinants act antagonistically in epithelial membrane polarisation, 
with Integrin and PI3K signalling localising PtdIns(3,4,5)P3 basally, and 
helping to restrict and/or orient PtdIns(4,5)P2, Cdc42 and the CRB3 complex 
apically (Akhtar and Streuli, 2013; Bryant et al., 2014; Fletcher et al., 2012; 
Martin-Belmonte et al., 2007; Thompson, 2013). Further work will be 
necessary to fully elaborate the molecular interactions that mediate the 
antagonistic relationship between apical and basal signals in cell polarisation 
and nuclear signalling via YAP. 
 
This fundamental control mechanism appears to be conserved across the 
animal kingdom. For example, Drosophila simple columnar epithelia such as 
imaginal discs rely primarily on apical Crb-Mer/Ex-Kibra-Sav signalling to 
retain Yki in the cytoplasm and restrict tissue growth (Baumgartner et al., 
2010; Chen et al., 2010; Genevet et al., 2010; Hamaratoglu et al., 2006; Ling 
et al., 2010; Yu et al., 2010). In contrast, Drosophila stratified columnar 
epithelia such as the intestine require Integrins, Src, EGFR, and Yki to 
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promote proliferation of basal layer stem/progenitor cells, suggesting that the 
regulatory connection between them described here may also be conserved 
(Cordero et al., 2014; Jiang et al., 2011; Kohlmaier et al., 2015; Lin et al., 
2013; Shaw et al., 2010; Staley and Irvine, 2010; Xu et al., 2011).  
Furthermore, ectopic activation of Src, EGFR, PI3K or Yki in simple columnar 
imaginal discs is sufficient to induce overproliferation of cells, while loss of 
PI3K or Yki strongly impairs imaginal disc tumour formation (Doggett et al., 
2011; Enomoto and Igaki, 2013; Fernandez et al., 2014; Herranz et al., 2012; 
Herranz et al., 2014; Strassburger et al., 2012; Willecke et al., 2011).  
 
Our model raises interesting questions about the possible physiological roles 
of other YAP regulators identified in cell culture, namely that YAP is controlled 
by Wnt signalling (Azzolin et al., 2014; Cai et al., 2015; Park et al., 2015), 
GPCR signalling (Yu et al., 2012), PKA signalling (Yu et al., 2013), LKB1-
MARK signalling (Mohseni et al., 2014), Protease-activated receptors (Mo et 
al., 2012), or the Mevalonate pathway (Sorrentino et al., 2014). Further work 
is necessary to understand in which tissues and under what conditions these 
diverse signals are utilised and integrated in vivo.   
 
Importantly, our model is easily reconciled with a possible role of YAP as a 
mechanosensor in epithelial tissues in vivo (Dupont et al., 2011). Mechanical 
force has been proposed to modulate signalling by both the apical Crb-
Mer/Ex-Kibra-Sav system in Drosophila (Fletcher et al., 2015; Rauskolb et al., 
2014) as well as the basal Integrin-Src system in mammalian cell culture 
(reviewed in (Humphrey et al., 2014; Lawson and Burridge, 2014)). In the 
early mouse pre-implantation embryo, cortical tension is higher in outer cells 
than inner cells, leading to nuclear YAP in outer cells despite the presence of 
an apical domain (Anani et al., 2014; Kono et al., 2014; Nishioka et al., 2009).  
Consistently, reducing cortical tension with ROCK inhibitor abolishes YAP 
nuclear localisation in early mouse embryos (Anani et al., 2014; Kono et al., 
2014; Nishioka et al., 2009). Mechanical forces may also explain why YAP 
becomes nuclear in some terminally differentiating and extremely flattened 
keratinocytes (Fig 5, cells marked by asterix).   
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Finally, our model is also easily reconciled with ability of YAP to respond to 
inflammatory cues in epithelia, such as Interleukin-6 (IL-6). Recent work 
revealed that the IL-6 co-receptor gp130 triggers stabilisation and nuclear 
translocation of YAP via Src kinases (Taniguchi et al., 2015). This signalling 
module was shown to be activated by mucosal injury to intestinal epithelia to 
promote intestinal regeneration, a known Src and YAP function (Cai et al., 
2010; Cordero et al., 2014; Taniguchi et al., 2015). We confirm that tissue 
damage (with 14Gy of radiation) elevates YAP levels in a Src-dependent 
manner in the intestine (Fig S7). However, we note that upon damage YAP is 
still most nuclear in basal crypt stem cells, which normally lack an apical 
domain, and mostly cytoplasmic in differentiated columnar epithelial cells, 
which have an apical domain (Fig S7). Interestingly, hyperproliferation per se 
driven by conditional deletion of APC and oncogenic mutation of KRAS  
(VillinCreER Apcfl/fl K-rasLSL-G12D) does not change the fundamental pattern of 
YAP localisation, with YAP remaining most strongly nuclear in the basal stem 
cells but not the columnar epithelial cells (Fig S6).  In the skin, YAP is also 
elevated upon wounding (Fig 2C,D) or inflammation (upon TPA treatment) in 
a Src-dependent manner (Fig 5), but remains most strongly nuclear in the 
basal layer stem/progenitor cell population (Fig 5). Thus, Src acts as a point of 
convergence between inflammatory cues and apical-basal polarity cues, with 
polarity cues being the dominant input. Further work is necessary to 
understand whether Src acts primarily by directly phosphorylating YAP or 
indirectly via enhancing PI3K signalling to inhibit MST-LATS activity. 
Nevertheless, our findings add weight to the notion that chemical inhibitors of 
Src kinases such as Dasatinib are promising cancer therapeutics (Creedon 
and Brunton, 2012; Karim et al., 2013) (Fig 8). 
 
In conclusion, epithelial stem/progenitor cell proliferation and differentiation 
may be regulated primarily by apical-basal polarity signals. In particular, YAP, 
a key driver of cell proliferation in stem/progenitor cells and cancer, appears 
to act primarily as a sensor of epithelial cell polarity and only secondarily as a 
sensor of other stimuli. Stem/progenitor cells thus use information about their 
polarity status to inform their decisions to either proliferate or 
arrest/differentiate via control of YAP. In the skin epithelium, nuclear YAP acts 
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redundantly with TAZ to drive gene expression in the basal stem/progenitor 
cell layer to maintain cell proliferation and normal tissue homeostasis.    
 
 
Materials and Methods 
 
siRNA treatment 
Human Caco‐ 2, A431 or HaCAT cells were cultured as previously stated 
(Fletcher et al., 2015, Elbediwy et al., 2012). All siRNA transfections were 
performed using Lipofectamine RNAiMax transfection reagent (invitrogen). 
Briefly cells were seeded in 6 well plates and treated with the 
siRNA/transfection mix 2 hours post seeding. A final concentration of 50-
100nM siRNA was used for transfections. The following day, another 
transfection was performed before the cells were trypsinised four hours later 
and reseeded either for 2D pr 3D culture. 2D siRNA treatments were left for a 
total of 72 hours, and 3D treatments were left for a total of 120 Hours. 3D 
cultures were prepared as previously stated (Elbediwy et al., 2012). siRNA 
were used as siGenome pools (Dharmacon). 
 
Inhibitor, blocking antibody and low calcium media treatments 
2D mammalian inhibitor treatments were for 4 hours,. The were as follows: 
5M PF573228 (FAK); 5M Saracatinib (Src); 5M Dasatinib (Src/Abl); 5M 
BX795 (PDK1); 5M MK2206 (AKT); 2M GDC0941 (PI3K); 100M 
Blebbistatin (Myosin); 100M Y27632 (Rock); 2M Latrunculin A (Actin) and 
3M Everolimus (mTOR). Integrin 1 blocking antibody or control IgG 
antibody was incubated with the cells for 1 hour at a concentration of 10g/ml 
before the cells were replated (Nancy Hogg). Low calcium conditions were as 
previously reported (Elbediwy et al., 2012). 2D wound healing involved plating 
the cells at high density, causing a scratch and subsequent addition of 
Dasatinib for 4 hours. 
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Antibodies, image acquisition and quantification 
-125), Mouse YAP (63.7), 
(Santa Cruz) and Rabbit pYAP), Samples were imaged with a Leica SP5 
confocal microscope using a 63x oil immersion objective, and processed 
using Adobe Photoshop. Fixation and cell culture quantification was carried 
out as previously described (Fletcher et al., 2015)  
 
Mouse strains 
All experiments were carried out in accordance with the United Kingdom 
Animal Scientific Procedures Act (1986) and UK home office regulations 
under project license number 70/7926. The Yap fl/fl Taz fl/fl mice were a kind 
gift from Axel Behrens (The Crick Institute) (manuscript in preparation). K5-
CreERt mice were obtained from Ian Rosewell (The Crick Institute). v-HA-Ras 
transgene (TG.AC) mice were a kind gift from Ilaria Malanchi (The Crick 
Institute) and have been previously described (Leder et al., 1990). Wildtype 
mice were used in mixed background. K5-CreERt Yap fl/fl Taz fl/fl and v-HA-
Ras transgene (TG.AC) mice were in mixed background and used with 
littermate controls.  APC p53 tumour sections from implanted nude mice were 
obtained from Owen Sansom (The Beatson Institute).  K14-Cre FAK fl/fl mice 
and Src fl/fl, Fyn-/-, Yes-/- mice were obtained from Val Brunton (Edinburgh) 
and described previously (Marcotte et al., 2012; Ridgway et al., 2012).  Apc-/- 
P53-/-  (Apc580D/580D P53 Trp53 2−10 allele) mice were obtained from Owen 
Sansom previously described (Jonkers et al., 2001; Shibata et al., 1997). 
AhCre is previously described (Ireland et al., 2004). K-rasG12D allele is from 
Tyler Jacks (Jackson et al., 2001). 
 
 
Yap/Taz conditional deletion 
Tamoxifen (Sigma, 20mg/ml in peanut oil) was injected intraperitoneally (IP) 
(5µl/g body weight) for 5 consecutive days into 8-16 week old controls or 
transgenic animals carrying K5-CreERt Yap fl/fl Taz fl/fl, animals to induce 
Yap/Taz knockdown and analyzed for Yap/Taz deficiency by 
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immunohistochemistry 7 days thereafter. K5-CreERt Yap fl/fl Taz fl/fl mice 
used for long-term analysis were subsequently IP injected with tamoxifen 
every month for 3 consecutive days and analyzed 8 weeks after the initial 
tamoxifen treatment start. 
 
Wound healing 
Following the 5-day tamoxifen treatment, 4 hydroxy-tamoxifen (4OHT, sigma) 
was topically applied to shaved backskin for 5 consecutive days at a dosage 
of 10mg/ml in Ethanol and 100 µl was applied per mouse. Mice were 
anaesthetized with IsoFlo® (Isoflurane, Abbott Animal Health) and treated 
with the analgesics Vetergesic® (Alstoe Animal Health) and RimadylTM (Pfizer 
Animal Health) for x days after wounding. A 4 mm punch wound was made in 
the backskin using a biopsy punch (Miltex) 10 days after tamoxifen/4OHT 
treatment start and wound closure monitored over time.  
 
Dasatinib treatment of skin 
Wildtype mice between 8-12 weeks of age were topically treated with 150 µl 
Dasatinib (10 µM in DMSO, Selleck) onto the shaved backskin directly 
followed by 200 µl TPA (12-O-tetradecanoylphorbol- 13-acetate; stock 
dissolved in DMSO and diluted in acetone, 12.5 µg/mouse) treatment for two 
consecutive days. Mice were analyzed and the backskin harvested on the 
third day. Control mice were treated with DMSO)/acetone.  
 
Chemical carcinogenesis 
Chemical skin carcinogenesis was induced on 12 week old v-Ha-Ras 
transgene (TG.AC)-expressing mice in mixed background by a single 
application of 100 µg/mouse DMBA (7,12-dimethylbenz(a)anthracene) onto 
the shaved backskin followed by biweekly topical treatments with TPA (4 
µg/mouse) starting one week after DMBA application. Skin papillomas were 
detectable 8 weeks DMBA-TPA treatment start and harvested at 13 weeks. 
For dasatinib treatment, papillomas allowed to reach an approximate size of 
~1 cm3. These established papillomas were treated topically with dasatinib 
(10 µM in DMSO/acetone; 100 µl/papilloma) once and analyzed 3 or 7 days 
thereafter. For generation of skin carcinomas, ~12 week old DMBA-treated 
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FVB/N wildtype mice were treated biweekly with 4 µg/mouse TPA onto 
shaved backskin for 10 weeks then weekly for a further 4 weeks before the 
carcinomas were harvested. 
Intestinal experiments 
Mice carrying the AhCre recombinase were induced by 3 daily intraperitoneal 
(i.p.) injection of 80 mg/kg β-Napthoflavone for one day. Intestinal phenotypes 
were analyzed 4 or 7 days after transgene induction to assess homeostasis or 
regeneration, respectively. Intestinal regeneration was induced by irradiating 
mice with 14Gy gamma-irradiation four days after recombinase induction. 
Mice were sacrificed 72h post irradiation and the small intestine isolated and 
flushed with tap water. 10x 1cm portions of small intestine were bound 
together with surgical tape and fixed in 4% neutral buffered formalin. 
 
Organoid transplantation experiments 
Intestinal crypts from VillinCreER Apcfl/fl P53fl/fl mice were removed 4 days 
following Cre induction with tamoxifen (2mg). This causes full recombination 
at both the APC and P53 loci and organoids now grow as sphere in an R-
Spondin independent manner (Sato et al., 2009). For transplantation of 
organoids, 50 organoids are transplanted subcutaneously into nude mice (see 
(Valeri et al., 2014). For dasatanib treatment, a dose of 10mg/kg daily gavage 
was chosen as we have previously shown to cause a reduction in p-SRC in 
vivo without toxicity (Morton et al., 2010). Mice were treated continuously from 
10 days post injection of spheres. 
 
Immunohistochemistry 
Mouse backskin samples were harvested and fixed in neutral-buffered 
formaldehyde 10% vol/vol and then embedded in paraffin blocks. 4uM thick 
sections were cut deparrinifised and rehydrated using standard methods. 
After an antigen retrieval step, sections were stained with Hematoxylin and 
Eosin (H&E) solution or with primary antibody. Additional images of human 
samples were obtained by data-mining the www.proteinatlas.org database 
(Berglund et al., 2008; Lundberg and Uhlen, 2010; Ponten et al., 2008; Uhlen 
et al., 2005; Uhlen et al., 2015; Uhlen et al., 2010). 
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RNAseq analysis 
A431 or HaCAT cell lysates  transfected with empty vector, YAP1 S5A,control 
siRNA  or YAP1 siRNAs were used.  Sequencing was performed on biological 
triplicates on the Illumina HiSeq 2500 platform and generated ~69 million 100 
bp paired end reads per sample. Sequenced reads were trimmed to 75 base 
pairs and mapped to the Refseq genome model, using RSEM (version 1.2.21).   
RSEM uses the bowtie2 alignment tool.  Gene counts were filtered to remove 
genes with 10 or fewer mapped reads per sample. TMM (treated mean of M-
values) normalisation and differential expression analysis using the negative 
binomial model was carried out with the R-Bioconductor package “EdgeR”. 
Genes with logCPM > 1 and FDR < 0.05 were judged to be differentially 
expressed. Enrichments of pathway-, category- and motif gene sets were 
assessed using GSEA with logFC pre-ranked gene lists. Gene sets with an 
enrichment false discovery rate (FDR) value of less than 0.05 were judged to 
be strongly statistically significant and values of less than 0.25 significant.  
 
qPCR 
 
Extraction of total RNA from Mouse skin was homogenised and extracted 
using an RNeasy Mini Kit (QIAGEN). cDNA synthesis for WT or dKO mice 
was performed using Superscript II (Invitrogen). Gene samples were run in 
triplicate on a Quantstudio 12 Flex Theromocycler. Expression values and 
quantitation was calculated using the ΔΔCT method relative to the 
housekeeping gene (B2M). S.E.M was used for the error bars. Primers were 
purchased as Quantitect Primers (Qiagen). 
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Figures 
 
 
 
Figure 1.  YAP & TAZ are expressed in both mouse & human skin and 
regulate gene expression in basal layer stem cells 
(A) Mouse skin is shown at three developmental stages, including embryonic 
(E17.5), Neonate and Adult. Tissue sections were stained for either YAP or 
TAZ to reveal their expression and subcellular localisation. 
(B) Human skin (Adult) stained for either YAP or TAZ. Note the nuclear 
localisation in basal layer stem/progenitor cells as well as terminally 
differentiating flattened cells. Other differentiating cells have cytoplasmic YAP 
and TAZ localisation. 
(C) Analysis of YAP-dependent gene expression by RNAseq was performed 
by comparison of YAP gain and loss of function in keratinocytes (see Fig S1). 
(D) YAP-regulated genes identified by RNAseq were analysed for their 
expression patterns in skin tissue by mining the Human Protein Atlas dataset 
(see methods). Strong enrichment in basal layer stem/progenitor cells was 
evident for many target genes, indicating that YAP and TAZ are 
transcriptionally active in this population of cells. 
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Figure 2.  Conditional inactivation of YAP and TAZ impairs skin 
homeostasis and wound repair in mice.   
(A) Control mice have a thick layer of hair (fur) covering their skin, which 
sections reveal is positive for YAP, TAZ and Ki67 (a marker of cell 
proliferation). 
(B) Double conditional knockout mice for YAP and TAZ treated with tamoxifen 
as adults or neonates exhibit dramatic hair loss. Adult skin sections are 
negative for YAP and TAZ as well as reduced in Ki67 positive cells 
(Quantified as a percentage of total interfollicular basal cells in each 
randomly-selected 40X field of view. n=757 ctrl cells; n=896 dKO cells).   
(C) Control mouse skin stained for YAP and TAZ. 
(D) Punch biopsy wound edge stained for YAP and TAZ. 
(E) Imaging of wound healing in control (n=8) and YAP/TAZ double 
conditional knockout mice (dKO; n=8). Note delayed healing in dKO. 
(F) Quantification of wound healing rates in control versus dKO animals.  
ImageJ was used to measure the wound area at each stage. 
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(G) Proliferation of cells as marked by Ki67 staining is reduced in dKO 
wounds versus control animals.  
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Figure 3.  Integrin-Src and EGFR-PI3K localisation in human stratified 
squamous epithelia and squamous cell carcinomas. 
The Human Protein Atlas dataset was mined to compare the expression and 
localisation of potential YAP regulators in human skin sections. 
(A) YAP staining reveals basal layer nuclear localisation across squamous 
tissue types and cancers. 
(B) ITGB1 staining reveals basal layer expression across squamous tissue 
types and cancers. 
(C) SRC staining reveals basal layer expression across squamous tissue 
types and cancers. 
(D) EGFR staining reveals basal layer expression across squamous tissue 
types and cancers. 
(E) AKT2 staining reveals basal subcellular localisation across squamous 
tissue types and cancers. 
(F) Model for YAP regulation in stratified squamous epithelia. 
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Figure 4.  Basal Integrin-Src signalling promotes YAP nuclear 
localisation in human HaCaT keratinocyte epithelial cells. 
(A) YAP nuclear localisation is prevented by treatment of keratinocytes with 
anti-ITGB1 antibodies (PD52) or by ITGB1 siRNA treatment, but not in 
controls. 
(B) YAP nuclear localisation is prevented by treatment of keratinocytes with 
the Src inhibitor Dasatinib, by the FAK inhibitor PF573228, or by the PI3K 
inhibitor GDC0941, but not by treatment with DMSO solvent.  
(C) YAP nuclear localisation is reduced by treatment of keratinocytes with the 
PDK1 inhibitor BX795, but not by the AKT inhibitor MK2206, TORC1 inhibitor 
Everolimus or DMSO solvent. 
(D) YAP nuclear localisation is reduced by treatment of keratinocytes with the 
F-actin destablising drug Latrunculin, the Myosin-II inhibitor Blebbistatin, or 
the Rho-kinase inhibitor Y27632. 
(E) Quantification of A-D. 
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(F) Western blotting analysis of phospho-YAP levels in keratinocytes treated 
with either DMSO control, PI3K inhibitor or Src inhibitor.  Total YAP levels are 
shown as a control. 
(G) Nuclear YAP localisation at the leading edge of a scratch wound in 
keratinocyte culture is abolished by treatment with the Src inhibitor Dasatinib. 
(H) Schematic diagram of YAP regulation in keratinocytes. 
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Figure 5.  Basal Integrin-Src signalling promotes YAP stability and 
nuclear localisation in mouse skin 
(A) YAP staining in control and TPA-treated skin to induce hyperplasia. 
(B) YAP staining is reduced in FAK conditional KO skin before or after 
treatment with TPA.  Note some residual nuclear YAP localisation in basal 
layer cells or highly flattened cells (*). 
(C) YAP staining is reduced in Src conditional KO skin before or after 
treatment with TPA.  Note some residual nuclear YAP localisation in basal 
layer cells or highly flattened cells (*). 
(D) YAP staining is reduced in Dasatinib-treated skin before or after treatment 
with TPA for two days.  Note some residual nuclear YAP localisation in basal 
layer cells or highly flattened cells (*). 
(E) YAP staining of mouse skin papilloma induced by DMBA-TPA treatment of 
v-Ha-Ras expressing mice (see methods).  Note stronger nuclear localisation 
in the basal layer. 
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(F) YAP staining of mouse skin squamous cell carcinoma induced by DMBA-
TPA treatment of v-Ha-Ras expressing mice. 
(G) YAP staining is strongly reduced by treatment of DMBA-TPA induced 
papillomas with the Src inhibitor Dasatinib topically for 3 days. 
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Figure 6.  Apical-domain formation inhibits YAP nuclear localisation in 
human columnar epithelia. 
The Human Protein Atlas dataset was mined to compare the localisation of 
YAP with the presence of absence of the apical domain in different epithelia.   
(A) YAP localises to the cytoplasm in columnar gallbladder epithelium, which 
expresses a CRB3-positive apical domain.  
(B) YAP localises to the cytoplasm in columnar endometrial epithelium, which 
expresses a CRB3-positive apical domain. 
(C) YAP localises to the nucleus of basal layer stem/progenitors, which lack 
CRB3 expression, and cytoplasm in columnar epithelial cells, which express a 
CRB3-positive apical domain, in the bronchus. 
(D) YAP localises to the nucleus of basal layer stem/progenitors, which lack 
CRB3 expression, and cytoplasm in columnar epithelial cells, which express a 
CRB3-positive apical domain, in the breast. 
(E) YAP localises to the cytoplasm in pseudostratified columnar bladder 
epithelium, which expresses a CRB3-positive apical domain.  
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(F) YAP localises to the nucleus of crypt base stem/progenitors, which lack a 
large CRB3-positive apical domain, and cytoplasm in columnar epithelial cells, 
which feature a large CRB3-positive apical domain, in the small intestine. 
(G) YAP localises to the nucleus of crypt base stem/progenitors, which lack a 
large CRB3-positive apical domain, and cytoplasm in columnar epithelial cells, 
which feature a large CRB3-positive apical domain, in the colon. 
(H) YAP localises to the nucleus of basal layer stem/progenitors, which lack 
CRB3 expression, and cytoplasm in columnar epithelial cells, which express a 
CRB3-positive apical domain, in the salivary gland. 
(I-L) YAP localises to the nucleus of basal layer stem/progenitors, and 
cytoplasm of differentiating squamous epithelial cells, even though the entire 
tissue lacks CRB3 expression. 
(M) Schematic diagram of YAP localisation in different epithelial tissue types. 
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Figure 7.  Basal Integrin-Src signalling promotes YAP nuclear 
localisation in human Caco2 epithelial cells when apical domain 
formation is blocked. 
(A) Caco2 colon adenocarcinoma cells form 3D cysts in cell culture that 
feature cytoplasmic YAP localisation. Silencing of Cdc42 by siRNA 
knockdown disrupts apical-basal polarity and induces more nuclear YAP 
localisation 
(B) Caco2 colon adenocarcinoma cells form 2D epithelial monolayers at high 
density.  Silencing of Cdc42 by siRNA knockdown disrupts apical-basal 
polarity and induces more nuclear YAP localisation, similar to silencing of 
LATS1/2. 
(C) YAP nuclear localisation is very strong when Caco2 cells are plated at low 
density to prevent apical domain formation. Nuclear localisation is prevented 
by treatment of Caco2 cells with low Calcium medium, anti-ITGB1 antibodies 
(PD52) or by ITGB1 siRNA treatment, but not in controls. 
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(D) YAP nuclear localisation is prevented by treatment of Caco2 cells with the 
Src inhibitor Dasatinib, by the FAK inhibitor PF573228, or by the PI3K inhibitor 
GDC0941, but not by treatment with DMSO solvent.  
(E) YAP nuclear localisation is reduced by treatment of Caco2 cells with the 
PDK1 inhibitor BX795, but not by the AKT inhibitor MK2206, TORC1 inhibitor 
Everolimus or DMSO solvent. 
(F) YAP nuclear localisation is reduced by treatment of Caco2 cells with the F-
actin destabilising drug Latrunculin, the Myosin-II inhibitor Blebbistatin, or the 
Rho-kinase inhibitor Y27632, or a combination of Blebbistatin and Y27532. 
(G) Quantification of C-F 
(H) Western blotting analysis of phospho-YAP levels in Caco2 cells treated 
with control siRNAs or ITGB1 siRNAs, as well as DMSO control, FAK inhibitor, 
PI3K inhibitor or Src inhibitor. Total YAP levels are shown as a control. 
(I) Schematic diagram of YAP regulation in Caco2 cells. 
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Figure 8. YAP becomes nuclear in invasive adenocarcinomas, which 
become sensitive to Dasatinib 
(A) In the colon, YAP localises to the cytoplasm of columnar epithelial cells in 
epithelial adenocarcinoma, and the nucleus of invasive adenocarcinoma cells, 
which have lost their columnar shape and lack a lumen. 
(B) In the stomach, YAP localises to the cytoplasm of columnar epithelial cells 
in epithelial adenocarcinoma, and the nucleus of invasive adenocarcinoma 
cells, which have lost their columnar shape and lack a lumen. 
(C) In the bronchus, YAP localises to the nucleus of basal layer 
stem/progenitors and cytoplasm in columnar epithelial cells in epithelial 
adenocarcinoma, and the nucleus of invasive adenocarcinoma, which have 
lost their columnar shape and lack a lumen. 
(D) In the endometrial epithelium, YAP localises to the cytoplasm of columnar 
epithelial cells in epithelial adenocarcinoma, and the nucleus of invasive 
adenocarcinoma cells, which have lost their columnar shape and lack a lumen. 
(E) In urothelial epithelium, YAP localises to the cytoplasm in pseudostratified 
columnar cells in epithelial adenocarcinoma, and to the nucleus of invasive 
adenocarcinoma, which have lost their columnar shape. 
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(F) YAP localises to the cytoplasm in ovarian adenocarcinoma, and to the 
nucleus of invasive ovarian andenocarcinoma, which have lost their columnar 
shape. 
(G) YAP staining in APC-/- p53-/- tumour organoids implanted subcutaneously 
into nude mice, which invade dramatically into the surrounding tissue. Note 
that cells at the invasive front feature nuclear YAP localisation, while columnar 
epithelial cells in the central regions of the tumour feature cytoplasmic YAP 
localisation. 
(H) YAP staining is strongly reduced by Dasatinib treatment of APC-/- p53-/- 
tumour organoids implanted subcutaneously into nude mice. Invasive tumour 
cells are not visible.  Quantification of YAP nuclear localisation was performed 
on n=200 tumour cells from G and H. 
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